Ex­clu­sive: Af­ter win­ning le­gal bat­tle, for­mer Phase­Bio in­vestor finds US buy­er for its PhI­II drug to re­verse Bril­in­ta

Hav­ing wran­gled con­trol of a blood thin­ner re­ver­sal agent, SFJ Phar­ma has found a buy­er for the drug.

SERB Phar­ma­ceu­ti­cals, a spe­cial­ty phar­ma that vast­ly ex­pand­ed its port­fo­lio through sev­er­al merg­ers in re­cent years, is pick­ing up US rights to ben­tracimab, which is de­signed to re­verse the an­ti-co­ag­u­lat­ing ef­fects of As­traZeneca’s Bril­in­ta (tica­grelor). Phase­Bio orig­i­nal­ly li­censed the drug from As­traZeneca’s for­mer bi­o­log­ics arm Med­Im­mune, and SFJ hopped aboard mid­way with de­vel­op­ment fund­ing. But when Phase­Bio sound­ed an alarm bell re­gard­ing the com­pa­ny’s fi­nances, SFJ de­mand­ed rights to the drug — and won the le­gal bat­tle ear­li­er this year. In the process, Phase­Bio al­so filed for Chap­ter 11 bank­rupt­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER